Zika vaccine pre-clinical and clinical data review with perspectives on the future development

References

• Anderson KB, Thomas SJ, Endy TP. The emergence of zika virus: a narrative review. Ann Intern Med. 2016;165:175–83. doi:10.7326/M16-0617.
   PubMed Web of Science ®Google Scholar
• Mier YT-RL, Delorey MJ, Sejvar JJ, Johansson MA. Guillain-Barre syndrome risk among individuals infected with Zika virus: a multi-country assessment. BMC Med. 2018;16:67. doi:10.1186/s12916-018-1052-4.
   PubMed Web of Science ®Google Scholar
• Carod-Artal FJ. Neurological complications of Zika virus infection. Expert Rev Anti Infect Ther. 2018;16:399–410. doi:10.1080/14787210.2018.1466702.
   PubMed Web of Science ®Google Scholar
• da Silva IRF, Frontera JA, Bispo de Filippis AM, Nascimento O, Group R-G-ZR. Neurologic complications associated with the Zika virus in Brazilian adults. JAMA Neurol. 2017. doi:10.1001/jamaneurol.2017.1703.
   PubMed Web of Science ®Google Scholar
• Marques VM, Santos CS, Santiago IG, Marques SM, Nunes Brasil MDG, Lima TT, Costa PS. Neurological complications of congenital Zika virus infection. Pediatr Neurol. 2019;91:3–10. doi:10.1016/j.pediatrneurol.2018.11.003.
   PubMed Web of Science ®Google Scholar
• Zou J, Shi PY. Strategies for Zika drug discovery. Curr Opin Virol. 2019;35:19–26. doi:10.1016/j.coviro.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Maurice J. WHO reveals its shopping list for weapons against Zika. Lancet. 2016;387:733. doi:10.1016/S0140-6736(16)00390-1.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Phimister EG. Zika Virus Vaccines - A Full Field and Looking for the Closers. N Engl J Med. 2017;376:1883–86. doi:10.1056/NEJMcibr1701402.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Giersing BK, Kaslow DC, Griffiths E, Meyer H, Barrett A, Durbin AP, Wood D, Hombach J. Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine. 2019;37:7443–50.
   Google Scholar
• Vannice KS, Cassetti MC, Eisinger RW, Hombach J, Knezevic I, Marston HD, Wilder-Smith A, Cavaleri M, Krause PR. Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine. 2019;37:863–68. doi:10.1016/j.vaccine.2018.12.040.
   PubMed Web of Science ®Google Scholar
• Gruber MF, Krause PR. Regulating vaccines at the FDA: development and licensure of Zika vaccines. Expert Rev Vaccines. 2017;16:525–27. doi:10.1080/14760584.2017.1324304.
   PubMed Web of Science ®Google Scholar
• Gruber MF, Farizo KM, Pratt RD, Fink DL, Finn TM, Krause PR, Borio LL, Marks PW. Clinical development strategies and considerations for zika vaccine licensure. J Infect Dis. 2017;216:S964–S70. doi:10.1093/infdis/jix433.
   PubMed Web of Science ®Google Scholar
• Cohen J. Steep drop in Zika cases undermines vaccine trial. Science. 2018;361:1055–56. doi:10.1126/science.361.6407.1055.
   PubMed Web of Science ®Google Scholar
• Cohen J. Where has all the Zika gone? Science. 2017;357:631–32. doi:10.1126/science.357.6352.631.
   PubMed Web of Science ®Google Scholar
• Miner JJ, Diamond MS. Zika virus pathogenesis and tissue tropism. Cell Host Microbe. 2017;21:134–42. doi:10.1016/j.chom.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Mattiuzzo G, Knezevic I, Hassall M, Ashall J, Myhill S, Faulkner V, Hockley J, Rigsby P, Wilkinson DE, Page M, collaborative study participants. Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. NPJ Vaccines. 2019 Oct;4:42. eCollection 2019. PMID: 31632743. doi:10.1038/s41541-019-0135-3.
   PubMed Web of Science ®Google Scholar
• Barrett ADT. Current status of Zika vaccine development: zika vaccines advance into clinical evaluation. NPJ Vaccines. 2018;3:24. doi:10.1038/s41541-018-0061-9.
   PubMed Web of Science ®Google Scholar
• Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng’ang’a D, Kirilova M, Nityanandam R, et al. Vaccine protection against Zika virus from Brazil. Nature. 2016;536:474–78. doi:10.1038/nature18952.
   PubMed Web of Science ®Google Scholar
• Bowen JR, Zimmerman MG, Suthar MS. Taking the defensive: immune control of Zika virus infection. Virus Res. 2018;254:21–26. doi:10.1016/j.virusres.2017.08.018.
   PubMed Web of Science ®Google Scholar
• Morrison TE, Diamond MS. Animal models of Zika virus infection, pathogenesis, and immunity. J Virol. 2017;91.
   Google Scholar
• Yi G, Xu X, Abraham S, Petersen S, Guo H, Ortega N, Shankar P, Manjunath N. A DNA vaccine protects human immune cells against Zika virus infection in humanized mice. EBioMedicine. 2017;25:87–94. doi:10.1016/j.ebiom.2017.10.006.
   PubMed Web of Science ®Google Scholar
• Cao B, Diamond MS, Mysorekar IU. Maternal-Fetal Transmission of Zika Virus: routes and Signals for Infection. J Interferon Cytokine Res. 2017;37:287–94. doi:10.1089/jir.2017.0011.
   PubMed Web of Science ®Google Scholar
• Caine EA, Jagger BW, Diamond MS. Animal models of Zika virus infection during pregnancy. Viruses. 2018;10.
   PubMed Web of Science ®Google Scholar
• Li XF, Dong HL, Wang HJ, Huang XY, Qiu YF, Ji X, Ye Q, Li C, Liu Y, Deng Y-Q, et al. Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone. Nat Commun. 2018;9:673. doi:10.1038/s41467-018-02975-w.
   PubMed Web of Science ®Google Scholar
• Kum DB, Mishra N, Boudewijns R, Gladwyn-Ng I, Alfano C, Ma J, Schmid MA, Marques RE, Schols D, Kaptein S, et al. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. NPJ Vaccines. 2018;3:56. doi:10.1038/s41541-018-0092-2.
   PubMed Web of Science ®Google Scholar
• Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et al. Modified mRNA vaccines protect against zika virus infection. Cell. 2017;168:1114–25 e10. doi:10.1016/j.cell.2017.02.017.
   PubMed Web of Science ®Google Scholar
• Zhu X, Li C, Afridi SK, Zu S, Xu JW, Quanquin N, Yang H, Cheng G, Xu Z. E90 subunit vaccine protects mice from Zika virus infection and microcephaly. Acta Neuropathol Commun. 2018;6:77. doi:10.1186/s40478-018-0572-7.
   PubMed Web of Science ®Google Scholar
• Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong W-P, et al. A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. Nat Commun. 2017;8:676. doi:10.1038/s41467-017-00737-8.
   PubMed Web of Science ®Google Scholar
• Siddharthan V, Van Wettere AJ, Li R, Miao J, Wang Z, Morrey JD, Julander JG. Zika virus infection of adult and fetal STAT2 knock-out hamsters. Virology. 2017;507:89–95. doi:10.1016/j.virol.2017.04.013.
   PubMed Web of Science ®Google Scholar
• Siddharthan V, Miao J, Van Wettere AJ, Li R, Wu H, Sullivan E, Jiao J, Hooper JW, Safronetz D, Morrey JD. Human polyclonal antibodies produced from transchromosomal bovine provides prophylactic and therapeutic protections against Zika virus infection in STAT2 KO Syrian Hamsters. Viruses. 2019;11.
   PubMed Web of Science ®Google Scholar
• Miller LJ, Nasar F, Schellhase CW, Norris SL, Kimmel AE, Valdez SM, Wollen-Roberts SE, Shamblin JD, Sprague TR, Lugo-Roman LA, et al. Zika virus infection in Syrian golden hamsters and strain 13 guinea pigs. Am J Trop Med Hyg. 2018;98:864–67. doi:10.4269/ajtmh.17-0686.
   PubMed Web of Science ®Google Scholar
• Kumar M, Krause KK, Azouz F, Nakano E, Nerurkar VR. A guinea pig model of Zika virus infection. Virol J. 2017;14:75. doi:10.1186/s12985-017-0750-4.
   PubMed Web of Science ®Google Scholar
• Deng YQ, Zhang NN, Li XF, Wang YQ, Tian M, Qiu YF, Fan J-W, Hao J-N, Huang X-Y, Dong H-L, et al. Intranasal infection and contact transmission of Zika virus in guinea pigs. Nat Commun. 2017;8:1648. doi:10.1038/s41467-017-01923-4.
   PubMed Web of Science ®Google Scholar
• Bierle CJ, Fernandez-Alarcon C, Hernandez-Alvarado N, Zabeli JC, Janus BC, Putri DS, Schleiss MR. Assessing Zika virus replication and the development of Zika-specific antibodies after a mid-gestation viral challenge in guinea pigs. PLoS One. 2017;12:e0187720. doi:10.1371/journal.pone.0187720.
   PubMed Web of Science ®Google Scholar
• Medina LO, To A, Lieberman MM, Wong TAS, Namekar M, Nakano E, Andersen H, Yalley-Ogunro J, Greenhouse J, Higgs S, et al. a recombinant subunit based zika virus vaccine is efficacious in non-human primates. Front Immunol. 2018;9:2464. doi:10.3389/fimmu.2018.02464.
   PubMed Web of Science ®Google Scholar
• Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, et al. Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS One. 2018;13:e0202820. doi:10.1371/journal.pone.0202820.
   PubMed Web of Science ®Google Scholar
• Kudchodkar SB, Choi H, Reuschel EL, Esquivel R, Jin-Ah Kwon J, Jeong M, Maslow JN, Reed CC, White S, Kim JJ, et al. Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. Microbes Infect. 2018;20:676–84. doi:10.1016/j.micinf.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–51. doi:10.1038/nature21428.
   PubMed Web of Science ®Google Scholar
• Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Nganga D, Nanayakkara O, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353:1129–32. doi:10.1126/science.aah6157.
   PubMed Web of Science ®Google Scholar
• Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354:237–40. doi:10.1126/science.aai9137.
   PubMed Web of Science ®Google Scholar
• Erratum for the Research Article: “Durability and correlates of vaccine protection against Zika virus in rhesus monkeys” by P. Abbink, R. A. Larocca, K. Visitsunthorn, M. Boyd, R. A. De La Barrera, G. D. Gromowski, M. Kirilova, R. Peterson, Z. Li, O. Nanayakkara, R. Nityanandam, N. B. Mercado, E. N. Borducchi, A. Chandrashekar, D. Jetton, S. Mojta, P. Gandhi, J. LeSuer, S. Khatiwada, M. G. Lewis, K. Modjarrad, R. G. Jarman, K. H. Eckels, S. J. Thomas, N. L. Michael, D. H. Barouch. Sci Transl Med. 2018;10(450):eaau6861. doi:10.1126/scitranslmed.aau6861.
   Google Scholar
• Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, Kirilova M, Peterson R, Li Z, Nanayakkara O, et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med. 2017;9.
   Web of Science ®Google Scholar
• Van Rompay KKA, Keesler RI, Ardeshir A, Watanabe J, Usachenko J, Singapuri A, Cruzen C, Bliss-Moreau E, Murphy AM, Yee JL, et al. DNA vaccination before conception protects Zika virus-exposed pregnant macaques against prolonged viremia and improves fetal outcomes. Sci Transl Med. 2019;11.
   Google Scholar
• Magnani DM, Rogers TF, Beutler N, Ricciardi MJ, Bailey VK, Gonzalez-Nieto L, Briney B, Sok D, Le K, Strubel A, et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci Transl Med. 2017;9.
   Google Scholar
• Kilgore N, Nuzum EO. An interagency collaboration to facilitate development of filovirus medical countermeasures. Viruses. 2012;4:2312–16. doi:10.3390/v4102312.
   PubMed Web of Science ®Google Scholar
• Coelho SVA, Neris RLS, Papa MP, Schnellrath LC, Meuren LM, Tschoeke DA, Leomil L, Verçoza BRF, Miranda M, Thompson FL, et al. Development of standard methods for Zika virus propagation, titration, and purification. J Virol Methods. 2017;246:65–74. doi:10.1016/j.jviromet.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet. 2018;391:552–62. doi:10.1016/S0140-6736(17)33105-7.
   PubMed Web of Science ®Google Scholar
• Sarwar UN, Costner P, Enama ME, Berkowitz N, Hu Z, Hendel CS, Sitar S, Plummer S, Mulangu S, Bailer RT, et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J Infect Dis. 2015;211:549–57. doi:10.1093/infdis/jiu511.
   PubMed Web of Science ®Google Scholar
• Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, et al. Rapid and long-term immunity elicited by dna-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis. 2016;214:369–78. doi:10.1093/infdis/jiw111.
   PubMed Web of Science ®Google Scholar
• Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, et al. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med. 2017. doi:10.1056/NEJMoa1708120.
   Web of Science ®Google Scholar
• Anfasa F, Siegers JY, van der Kroeg M, Mumtaz N, Stalin Raj V, de Vrij FMS, Widagdo W, Gabriel G, Salinas S, Simonin Y, et al. Phenotypic differences between Asian and African Lineage Zika viruses in human neural progenitor cells. mSphere. 2017;2.
   Web of Science ®Google Scholar
• Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018;391:563–71. doi:10.1016/S0140-6736(17)33106-9.
   PubMed Web of Science ®Google Scholar
• Ramanathan R, Stibitz S, Pratt D, Roberts J. Use of controlled human infection models (CHIMs) to support vaccine development: US regulatory considerations. Vaccine. 2019;37:4256–61. doi:10.1016/j.vaccine.2019.06.009.
   PubMed Web of Science ®Google Scholar
• Pedro SA, Abelman S, Tonnang HE. Predicting rift valley fever inter-epidemic activities and outbreak patterns: insights from a stochastic host-vector model. PLoS Negl Trop Dis. 2016;10:e0005167. doi:10.1371/journal.pntd.0005167.
   PubMed Web of Science ®Google Scholar